Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — Investor Presentation (January 2021)
21 slides from Scopus Biopharma's investor presentation, Jan 20, 2021
Slide 1: Follow-On Offering Presentation January 2021
Follow - On Offering Presentation January 202 1
Slide 2: Disclaimers
Disclaimers Scopus BioPharma Inc . (“Scopus”) has filed an offering statement (including an offering circular) with the Securities and Exchange Commission (“SEC”) for the offering of Scopus shares of common stock to which this presentation relates . You should read the offering circular and other do
Slide 3: The Company
The Company 3 ➢ Scopus BioPharma is developing CpG - STAT3siRNA, or CO - sTiRNA TM , a ground - breaking cancer treatment encompassing both immunotherapy and gene therapy ➢ IND for Phase 1 clinical trial for B - cell Non - Hodgkin’s Lymphoma (“NHL ”) slated to be filed in H1 2021 ➢ Clinical trial an
Slide 4: The Company
The Company 4 ➢ Subsequent Phase 1 clinical trial expected for B - cell NHL in combination with immune checkpoint inhibitors and/or CAR - Ts ➢ We have an exclusive worldwide license for CO - sTiRNA from City of Hope National Medical Center (“COH”), a world - renowned research and cancer center near
Slide 5: Offering Summary
Issuer Scopus BioPharma Inc. Offering Size $ Common Stock Offered shares Offering Price Per Share $ per share Nasdaq Global Market Symbol “ SCPS” Common Stock Outstanding After Offerin g (1)(2)(3)(4) Use of Proceeds CO - sTiRNA clinical development and sponsored research, working capital and general
Slide 6: Highlights
Highlights 6 ➢ CO - sTiRNA is a potential game - changing treatment, making STAT3 “druggable ” ➢ Unique approach encompassing both immunotherapy and gene therapy ➢ H1 2021 filing of IND and H2 2021 initiation of Phase 1 clinical trial for CO - sTiRNA ➢ Near - term milestones provide multiple opportu
Slide 7: Pipeline
Pipeline Program aiid, Pre-Clinical Testing ) IND-Enabling Studies ) rset) ceIR Inverse Agonists = |
Slide 8: Near-Term Value Building Milestones
8 Near - Term Value Building Milestone s Q1 2021 » Complet ion of clinical l ot m anufacturing » Finalization of status report on research for CO - sTiRNA + checkpoint inhibitor under the SRA » Finalization of IND package for CO - sTiRNA for B - cell NHL Q2 2021 » Filing of IND for CO - sTiRNA for B
Slide 9: Additional Value Building Milestones
9 Additional Value Building Milestone s 2022 » Completion of supporting studies for CO - sTiRNA + checkpoint inhibitor » Filing/amendment of IND for CO - sTiRNA + checkpoint inhibitor for Phase 1 clinical trial » Commencement of CO - sTiRNA + checkpoint inhibitor Phase 1 clinical trial
Slide 10: Strategic Partners and Intellectual Property
10 ➢ We capitalize on o utstanding scientific and medical provenance based on pioneering discoveries at some of the world’s foremost research and academic institutions ➢ Exclusive worldwide licenses from COH , N IH and The Hebrew University of Jerusalem ➢ Our key drug candidates are covered by multi
Slide 11: Experienced Biopharma Leadership
Ashish P. Sanghrajka President and Director Aharon Schwartz, Ph.D. SAB Chairman Executive Chairman - Scopus Israel Morris C. Laster, M.D. SAB Member; Director and Senior Medical Advisor - Scopus Israel Raphael (Rafi) Hofstein, Ph.D. Director Lesley Russell, MB.Ch.B., MRCP Director Hua E. Yu, Ph.D. S
Slide 12: Experienced Finance and Capital Markets Leadership
Experienced Finance and Capital Markets Leadership Joshua R . Lamstein Chairman and Director Robert J. Gibson, CFA Vice Chairman and Director David S. Battleman, M.D. Director David A . Buckel, CMA Director Ira Scott Greenspan Director Paul E. Hopper Director David Weild IV Director 12
Slide 13: A Cancer Therapeutic Drug Candidate with Dual Activity
CO - sTiRNA : A Cancer Therapeutic Drug Candidate with Dual Activity ✓ Signal Transducer and Activator of Transcription 3 (STAT3) is a highly desirable target for cancer therapy. Importantly, STAT3 inhibition does not a ffect viability of normal cells. ✓ CO - sTiRNA strategy is a gene therapy, which
Slide 14: Why Targeting STAT3 is So Important for Cancer Therapy
➢ STAT3 is a critical convergence point for many cancer - causing pathways, promoting cancer cell survival, proliferation and invasion by regulating several genes involved in cell growth and division ➢ When STAT3 proteins are activated by various extracellular signals, they move into the cell nucleu
Slide 15: Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses
B16 Melanoma Model Wild type control Tumors are gone 15 • Black lines show C p G and STAT3 alone do not inhibit tumor growth effectively • Blue line shows that antitumor effects induced by taking away STAT3 and stimulating with CpG molecule are dependent on T cell activities • The antitumor effects
Slide 16: Pharmacology and Toxicology Studies
CO - sTiRNA : Pharmacology and Toxicology Studies ➢ No Cytokine Release Syndrome in vitro (human PBMC), no gross abnormalities in mouse and rat toxicology studies ➢ Completed initial toxicology study with CO - sTiRNA injected subcutaneously into male and female rats ➢ Subcutaneous injection (in rode
Slide 17: Overview of Phase 1 Clinical Trial
Indication Non - Hodgkin’s Lymphoma Population/ Indication(s): Relapsed/Refractory B - c ell Non - Hodgkin’s Lymphoma Phase Phase 1, with expansion cohort Segment Relapsed/ Recurrent Therapy Status At initial treatment No. of Patients 15 expected (4 - 24) Estimated Study / Duration 30 months Partici
Slide 18: Significant Investor Demand for Immuno-Oncology and Gene Therapy IPOs in 2020
Significant Investor Demand for Immuno - Oncology and Gene Therapy IPOs in 2020 18 Gross Post-money Return Company Ticker Date Price Proceeds Market Cap. Price Market Cap. (IPO to 12/31/20) Immuno-Oncology Silverback Therapeutics SBTX 12/03/20 $21.00 $278 $729 $46.34 $1,609 120.7% Kiromic BioPharma
Slide 19: MRI-1867
MRI - 1867 ➢ MRI - 1867 is a proprietary, dual - action, peripherally - restricted NCE CB 1 receptor (CB1R) inverse agonist and inhibitor of iNOS ➢ Over activation of CB 1 and iNOS has been implicated in the pathophysiology of systemic sclerosis, including fibrosis of the skin, lung, kidney and hear
Slide 20: Key Takeaways
Key Takeaways 20 ➢ Potential game - changing treatment making STAT3 “druggable” ➢ CO - sTiRNA stands out as both immunotherapy and gene therapy ➢ Value - driving, near - term milestones ➢ Multi - billion dollar market opportunities ➢ High barriers to entry ➢ Attractive drug candidates with moderate
Slide 21: Thank You
AA SCOPUS BIOPHARMA Thank You
Scopus BioPharma — Investor Presentation (January 2021) on 6ix